{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T05:59:16Z","timestamp":1769061556732,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["FLUME15A0"],"award-info":[{"award-number":["FLUME15A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["GOSS15A0"],"award-info":[{"award-number":["GOSS15A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["HELTSH15A0"],"award-info":[{"award-number":["HELTSH15A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["SANDER14A0"],"award-info":[{"award-number":["SANDER14A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["SANDER17AB0"],"award-info":[{"award-number":["SANDER17AB0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["WEST15A0"],"award-info":[{"award-number":["WEST15A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["WEST17AB0"],"award-info":[{"award-number":["WEST17AB0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["WEST17Y5"],"award-info":[{"award-number":["WEST17Y5"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001450"],"award-info":[{"award-number":["UL1 TR001450"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"National Institute of Health and Medical Research","doi-asserted-by":"publisher","award":["P30 DK089507"],"award-info":[{"award-number":["P30 DK089507"]}],"id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jcf.2022.04.006","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T21:44:15Z","timestamp":1650577455000},"page":"753-758","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Antipseudomonal treatment decisions during CF exacerbation management"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5727-8164","authenticated-orcid":false,"given":"D.R.","family":"VanDevanter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.E.","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6265-6249","authenticated-orcid":false,"given":"D.B.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4818-5828","authenticated-orcid":false,"given":"M.","family":"Skalland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8602-0309","authenticated-orcid":false,"given":"C.H.","family":"Goss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.A.","family":"Flume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.L.","family":"Heltshe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jcf.2022.04.006_bib0001","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jpeds.2007.03.006","article-title":"Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis","volume":"151","author":"Konstan","year":"2007","journal-title":"J Pediatr"},{"issue":"5","key":"10.1016\/j.jcf.2022.04.006_bib0002","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jcf.2012.03.009","article-title":"Risk factors for rate of decline in FEV1 in adults with cystic fibrosis","volume":"11","author":"Konstan","year":"2012","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2022.04.006_bib0003","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/aje\/153.4.345","article-title":"Predictive 5-year survivorship model of cystic fibrosis","volume":"153","author":"Liou","year":"2001","journal-title":"Am J Epidemiol"},{"issue":"12 Pt 1","key":"10.1016\/j.jcf.2022.04.006_bib0004","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1164\/rccm.200202-087OC","article-title":"Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality","volume":"166","author":"Mayer-Hamblett","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"9358","key":"10.1016\/j.jcf.2022.04.006_bib0005","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(03)12567-6","article-title":"Cystic fibrosis","volume":"361","author":"Ratjen","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2022.04.006_bib0006","series-title":"Clinical practice guidelines for cystic fibrosis","year":"1997"},{"issue":"9","key":"10.1016\/j.jcf.2022.04.006_bib0007","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.jcf.2022.04.006_bib0008","article-title":"Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis","volume":"12","author":"Elphick","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.jcf.2022.04.006_bib0009","article-title":"Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis","volume":"6","author":"Holland","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.jcf.2022.04.006_bib0010","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/infdis\/147.3.559","article-title":"Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo","volume":"147","author":"McLaughlin","year":"1983","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.jcf.2022.04.006_bib0011","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/00006454-198707000-00006","article-title":"Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary infections in cystic fibrosis","volume":"6","author":"Padoan","year":"1987","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.jcf.2022.04.006_bib0012","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0022-3476(99)70197-6","article-title":"Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis","volume":"134","author":"Smith","year":"1999","journal-title":"J Pediatr"},{"issue":"5","key":"10.1016\/j.jcf.2022.04.006_bib0013","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ppul.1060","article-title":"Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study","volume":"31","author":"Master","year":"2001","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.jcf.2022.04.006_bib0014","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10096-005-0076-9","article-title":"Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients","volume":"25","author":"Balke","year":"2006","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"10.1016\/j.jcf.2022.04.006_bib0015","article-title":"Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis","volume":"5","author":"Smith","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.jcf.2022.04.006_bib0016","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.prrv.2007.04.005","article-title":"Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms","volume":"8","author":"Aaron","year":"2007","journal-title":"Paediatr Respir Rev"},{"issue":"2","key":"10.1016\/j.jcf.2022.04.006_bib0017","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jcf.2020.11.020","article-title":"Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: ototoxicity following tobramycin treatment","volume":"20","author":"Harruff","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcf.2022.04.006_bib0018","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/ppul.23718","article-title":"Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients","volume":"52","author":"LeCleir","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2022.04.006_bib0019","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202102-0461OC","article-title":"A randomized trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment","author":"Goss","year":"2021","journal-title":"Am J Respir Crit Care Med."},{"issue":"3","key":"10.1016\/j.jcf.2022.04.006_bib0020","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jcf.2015.10.006","article-title":"IV-treated pulmonary exacerbations in the prior year: an important independent risk factor for future pulmonary exacerbation in cystic fibrosis","volume":"15","author":"VanDevanter","year":"2016","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.04.006_bib0021","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jcf.2017.06.002","article-title":"Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor","volume":"17","author":"Flume","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"9","key":"10.1016\/j.jcf.2022.04.006_bib0022","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/cid\/ciab525","article-title":"Association between number of intravenous antipseudomonal antibiotics and clinical outcomes of pediatric cystic fibrosis pulmonary exacerbations","volume":"73","author":"Cogen","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"7441","key":"10.1016\/j.jcf.2022.04.006_bib0023","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/bmj.38028.520995.63","article-title":"Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials","volume":"328","author":"Paul","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.jcf.2022.04.006_bib0024","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3389\/fncel.2017.00308","article-title":"Aminoglycoside-induced cochleotoxicity: a review","volume":"11","author":"Jiang","year":"2017","journal-title":"Front Cell Neurosci"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322000960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322000960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:47:19Z","timestamp":1761601639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199322000960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1569199322000960"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2022.04.006","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antipseudomonal treatment decisions during CF exacerbation management","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2022.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}